RESEARCH PAPER
Concentration of LDLR, degree of hepatic fibrosis and hepatic steatosis in patients with chronic hepatitis B infection treated with tenofovir disoproxil fumarate
 
More details
Hide details
1
Medical University, Lublin, Poland
CORRESPONDING AUTHOR
Agnieszka Pokora - Rodak   

Medical University of Lublin, Staszica 16, 20-081, Lublin, Poland
 
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Epidemiological data indicate that one-third of the world’s population have serological markers of hepatitis B virus infection. Hepatic steatosis is often observed in patients with chronic liver diseases. The exact mechanisms of hepatic steatosis progression and the efficacy of antiviral therapy in patients with CHB and hepatic steatosis are not yet fully understood.

Objective:
The aim of the study was to investigate the LDLR concentration and degree of hepatic fibrosis and hepatic steatosis in patients with chronic hepatitis B infection during tenofovir disoproxil fumarate therapy.

Material and methods:
The study group consisted of 54 patients with CHB. The LDLR concentration, assessment of the degree of hepatic fibrosis, hepatic steatosis, total cholesterol, low density lipoprotein, high density lipoprotein and triglyceride concentrations, were assessed at the beginning of therapy, 6 months later, and 12 months after commencement of therapy. The control group consisted of 18 healthy individuals.

Results:
The mean LDLR concentration in the studied groups was statistically significantly lower (p<0.05) than in the controls. The antiviral therapy based on TDF had no influence on the LDLR concentration and HBsAg level.

Conclusions:
The results indicate a statistically significant lower(p<0.05) concentration of LDLR in patients with chronic hepatitis B infection. Negative correlations between HBsAg level and LDLR concentration in patients with chronic HBV, at all stages of the study may indicate, that HBsAg protects hepatocytes from LDL accumulation.

 
REFERENCES (24)
1.
Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol. 2003; 39: 64–69.
 
2.
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017; 67: 862–873.
 
3.
Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111–117.
 
4.
Zhu Y, Yang Q, Lv F, Yu Y. The effect of hepatosteatosis on response to antiviral treatment in patients with chronic hepatitis B: a metanalysis. Gastroenterol Res Pract. 2017; 2017: 1096406.
 
5.
Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129: 113–121.
 
6.
Wang CC, Tseng TC, Kao JH. Hepatitis B virus infection and metabolic syndrome: fact or fiction? J Gastroenterol Hepatol. 2015; 30: 14–20.
 
7.
Xiong J, Zhang H, Wang Y, Wang A, Bian J, Huang H, Zheng Y, Sang X, Xu Y, Lu X Zhao H. Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis. Oncotarget. 2017 Nov 3; 8(63): 107295–107302. doi: 10.18632/oncotarget.22364. eCollection 2017 Dec 5.
 
8.
Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, Iloeje UH, Chen CJ. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010; 139: 474–482.
 
9.
Kang SK, Chung TW, Lee JY, Lee YC, Morton RE, Kim CH. The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of Nacetylglucosaminyltransferase III. J Biol Chem. 2004; 279: 28106– 28112.
 
10.
Chen JY, Wang JH, Lin CY, Chen PF, Tseng PL, Chen CH, Chang KC, Tsai LS, Chen SC, Lu SN. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B, C strains independently. J Gastroenterol Hepatol. 2010; 25: 1763–1768.
 
11.
Li YJ, Zhu P, Liang Y, Yin WG, Xiao JH. Hepatitis B virus induces expression of cholesterol metabolism-related genes via TLR2 in HepG2 cells. World J Gastroenterol. 2013; 19: 2262–2269.
 
12.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009; 50: 227–242.
 
13.
Marcellin P, Gane E, Buti M. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468–475.
 
14.
Clercq ED, Férir G, Kaptein S, Neyts J. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections Viruses. 2010 Jun; 2(6): 1279–1305.
 
15.
Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993; 1885–1893.
 
16.
Hong Yu Wang, Chao Quan, Chunxiu Hu, Bingxian Xie, Yinan Du, Liang Chen, Wei Yang, Liu Yang, Qiaoli Chen, Bin Shen, et al. A lipidomics study reveals hepatic lipid signatures associating with deficiency of the LDL receptor in a rat model. Biology Open 2016; 5: 979–986. doi:10.1242/bio.019802.
 
17.
Wang MM, Wang GS, Shen F. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014; 59: 2571–2579.
 
18.
Sundeep K, Goyal, Ashok K Jain, Vinod K Dixit, Suneet K Shukla, Mohan Kumary, Jayant Ghosh, Arttrika Ranjan, Neha Gupta, Manish Tripathi. HBsAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With Chronic Hepatitis B Virus Infection. J Clin Exp Hepatol. 2015; 5(3); 213–220.
 
19.
Rastogi A, Sakhuja P, Kumar A. Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol. 2011; 54: 454–459.
 
20.
Dogan Z, Filik L, Ergül B. Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis. Saudi J Gastroenterol. 2015; 21: 396–399.
 
21.
Yimaz B, Koklu S, Buyukbayram H, Yalcin K, Korkmaz U, Posul E. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis. Afr Health Sci. 2015 Sep; 15(3): 714–718. doi: 10.4314/ahs.v15i3.3.
 
22.
Machado MV, Oliveire AG, Cortez-Pinto H. Hepatic steatosis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011; 26: 1361–1367.
 
23.
Lesmana LA, Lesmana CR, Pakasi LS, Krisnuhoni E. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. Acta Med Indones. 2012; 44: 35–39.
 
24.
Minakari M, Molaei M, Shalmani HM. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. Eur J Gastroenterol Hepatol. 2009; 21: 512–516.
 
eISSN:1898-2263
ISSN:1232-1966